Re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder” by Strawn et al.—Concerning Harm–Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety Disorder-Reference-Cited by-同舟云学术

Re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder” by Strawn et al.—Concerning Harm–Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety Disorder

Published:2023-09-01 Issue:7 Volume:33 Page:295-296
ISSN:1044-5463
Container-title:Journal of Child and Adolescent Psychopharmacology
language:en
Short-container-title:Journal of Child and Adolescent Psychopharmacology

Author:

Plöderl Martin¹^ORCID,Horowitz Mark A.²³,Hengartner Michael P.⁴

Affiliation:

1. Center for Inpatient Psychotherapy and Crisis Intervention, Paracelsus Medical University Salzburg, Salzburg, Austria.

2. Research and Development Department, Goodmayes Hospital, North East London NHS Foundation Trust, Ilford, United Kingdom.

3. Division of Psychiatry, University College London, London, United Kingdom (honorary affiliation).

4. Department of Applied Psychology, Zurich University of Applied Sciences, Zurich, Switzerland.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Psychiatry and Mental health,Pediatrics, Perinatology and Child Health

Link

https://www.liebertpub.com/doi/pdf/10.1089/cap.2023.0029

Reference4 articles.

1. Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review

2. Paediatric antidepressants: Benefits and risks

3. Treatment-Emergent Sexual Dysfunction Related to Antidepressants

4. A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response to Plöderl et al. re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder”;Journal of Child and Adolescent Psychopharmacology;2024-03-01